Inventor · disambiguated record
Tao Wu
Also filed as: WU TAO
56 granted patents·23 pending applications·614 citations·filing 2001–2025
98Inventor score
Files withARAXES PHARMA LLC33KURA ONCOLOGY INC20GILEAD SCIENCES INC4BOEHRINGER INGELHEIM INT3CHATTERJEE ARNAB K3
Top patents by PatentIndex Score
79 records- 0198US10144724B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Dec 4, 2018·44 cites·42 claims
- 0297US10745385B2Covalent inhibitors of KRASARAXES PHARMA LLC·Filed 2018·Granted Aug 18, 2020·17 cites·54 claims
- 0397US10377743B2Inhibitors of RAS and methods of use thereofARAXES PHARMA LLC·Filed 2017·Granted Aug 13, 2019·29 cites·31 claims
- 0497US10370386B2Substituted quinolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2017·Granted Aug 6, 2019·33 cites·30 claims
- 0597US10351550B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2018·Granted Jul 16, 2019·27 cites·32 claims
- 0697US10246424B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Apr 2, 2019·36 cites·90 claims
- 0797US9926267B2Covalent inhibitors of K-Ras G12CARAXES PHARMA LLC·Filed 2015·Granted Mar 27, 2018·38 cites·35 claims
- 0897US9840516B2Substituted quinazolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2014·Granted Dec 12, 2017·73 cites·33 claims
- 0997US9227978B2Covalent inhibitors of Kras G12CARAXES PHARMA LLC·Filed 2014·Granted Jan 5, 2016·47 cites·24 claims
- 1096US11673898B2Substituted inhibitors of menin-MLL and methods of useKURA ONCOLOGY INC·Filed 2020·Granted Jun 13, 2023·6 cites·27 claims
- 1196US10927125B2Substituted cinnolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2019·Granted Feb 23, 2021·11 cites·29 claims
- 1296US10919850B2Covalent inhibitors of KRas G12CARAXES PHARMA LLC·Filed 2019·Granted Feb 16, 2021·9 cites·38 claims
- 1396US10829458B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2019·Granted Nov 10, 2020·13 cites·29 claims
- 1496US10781218B2Substituted inhibitors of menin-MLL and methods of useKURA ONCOLOGY INC·Filed 2017·Granted Sep 22, 2020·16 cites·20 claims
- 1596US10414757B22-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Sep 17, 2019·33 cites·49 claims
- 1696US10273207B2Covalent inhibitors of kras G12CARAXES PHARMA LLC·Filed 2018·Granted Apr 30, 2019·24 cites·34 claims
- 1796US10077271B2Methods and compositions for inhibiting the interaction of menin with MLL proteinsKURA ONCOLOGY INC·Filed 2017·Granted Sep 18, 2018·14 cites·18 claims
- 1895US10736897B2Compounds and methods of use thereof for treatment of cancerARAXES PHARMA LLC·Filed 2018·Granted Aug 11, 2020·28 cites·15 claims
- 1995US10428064B2Fused-tricyclic inhibitors of KRAS and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Oct 1, 2019·27 cites·28 claims
- 2094US11878985B2Substituted quinazolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2020·Granted Jan 23, 2024·2 cites·43 claims
- 2194US11377441B2Covalent inhibitors of KRASARAXES PHARMA LLC·Filed 2020·Granted Jul 5, 2022·3 cites·28 claims
- 2294US11021470B22-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereofARAXES PHARMA LLC·Filed 2019·Granted Jun 1, 2021·8 cites·21 claims
- 2393US10752639B2Bridged bicyclic inhibitors of menin-MLL and methods of useKURA ONCOLOGY INC·Filed 2017·Granted Aug 25, 2020·8 cites·14 claims
- 2492US11325891B2Processes and intermediates for preparing MCL1 inhibitorsGILEAD SCIENCES INC·Filed 2020·Granted May 10, 2022·8 cites·2 claims
- 2592US10588907B2Methods and compositions for inhibiting the interaction of menin with MLL proteinsKURA ONCOLOGY INC·Filed 2016·Granted Mar 17, 2020·6 cites·1 claims
- 2692US10174041B2Methods and compositions for inhibiting the interaction of menin with MLL proteinsKURA ONCOLOGY INC·Filed 2018·Granted Jan 8, 2019·11 cites·24 claims
- 2790US11760736B2Processes and intermediates for preparing MCL1 inhibitorsGILEAD SCIENCES INC·Filed 2022·Granted Sep 19, 2023·2 cites·15 claims
- 2889US10246464B2Thienopyrimidine and thienopyridine compounds and methods of use thereofUNIV MICHIGAN REGENTS·Filed 2015·Granted Apr 2, 2019·9 cites·20 claims
- 2988US11542248B2Methods and compositions for inhibiting the interaction of menin with MLL proteinsKURA ONCOLOGY INC·Filed 2018·Granted Jan 3, 2023·4 cites·14 claims
- 3088US11274093B2Fused bicyclic benzoheteroaromatic compounds and methods of use thereofARAXES PHARMA LLC·Filed 2018·Granted Mar 15, 2022·4 cites·16 claims
- 3188US2024352028A1Substituted quinazolines as inhibitors of kras g12cARAXES PHARMA LLC·Filed 2024·Application pending·0 cites
- 3287US9624228B2Inhibitors of ERK and methods of useKURA ONCOLOGY INC·Filed 2014·Granted Apr 18, 2017·3 cites·17 claims
- 3386US9901642B2Amine-containing transfection reagents and methods for making and using sameLIFE TECHNOLOGIES CORP·Filed 2014·Granted Feb 27, 2018·3 cites·16 claims
- 3484US11555041B2Bridged bicyclic inhibitors of menin-MLL and methods of useKURA ONCOLOGY INC·Filed 2020·Granted Jan 17, 2023·1 cites·10 claims
- 3584US2025154133A1Covalent inhibitors of krasARAXES PHARMA LLC·Filed 2024·Application pending·0 cites
- 3684US2024043441A1Inhibitors of kras g12cARAXES PHARMA LLC·Filed 2023·Application pending·0 cites
- 3784US2023303586A1Inhibitors of kras g12cARAXES PHARMA LLC·Filed 2023·Application pending·0 cites
- 3883USRE50527ECovalent inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2023·Granted Aug 12, 2025·0 cites·41 claims
- 3981US12234244B2Substituted piperazines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2022·Granted Feb 25, 2025·0 cites·12 claims
- 4080USRE50490ESubstituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2022·Granted Jul 15, 2025·0 cites·29 claims
- 4178US12410146B2Processes and intermediates for preparing MCL1 inhibitorsGILEAD SCIENCES INC·Filed 2023·Granted Sep 9, 2025·0 cites·4 claims
- 4278US11793895B2Residualizing linkers and uses thereofCENTRE FOR PROBE DEV AND COMMERCIALIZATION·Filed 2020·Granted Oct 24, 2023·1 cites·24 claims
- 4378US11649251B2Substituted inhibitors of menin-MLL and methods of useKURA ONCOLOGY INC·Filed 2018·Granted May 16, 2023·1 cites·19 claims
- 4478US9951078B2Inhibitors of ERK and methods of useKURA ONCOLOGY INC·Filed 2017·Granted Apr 24, 2018·1 cites·29 claims
- 4577US11639346B2Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRASARAXES PHARMA LLC·Filed 2018·Granted May 2, 2023·2 cites·25 claims
- 4677US9963454B2Compounds and compositions for the treatment of parasitic diseaseCHATTERJEE ARNAB K·Filed 2015·Granted May 8, 2018·2 cites·13 claims
- 4776US9469645B2Compounds and compositions for the treatment of parasitic diseasesCHATTERJEE ARNAB K·Filed 2013·Granted Oct 18, 2016·3 cites·13 claims
- 4876US2024358703A1Methods for treating hematological malignancies and ewing's sarcomaKURA ONCOLOGY INC·Filed 2024·Application pending·0 cites
- 4976US2023203018A1Covalent inhibitors of krasARAXES PHARMA LLC·Filed 2022·Application pending·0 cites
- 5075US12415880B1POSS-based hybrid supercritical CO2 thickener and preparation method thereofUNIV SOUTHWEST PETROLEUM·Filed 2024·Granted Sep 16, 2025·0 cites·6 claims
Showing the top 50 of 79 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Tao Wu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →